| [1] |
COLL M, PEREA L, BOON R, et al. Generation of hepatic stellate cells from human pluripotent stem cells enables in vitro modeling of liver fibrosis[J]. Cell Stem Cell, 2018, 23(1): 101-113.e7. DOI: 10.1016/j.stem.2018.05.027. |
| [2] |
MEHTA KJ, FARNAUD SJ, SHARP PA. Iron and liver fibrosis: Mechanistic and clinical aspects[J]. World J Gastroenterol, 2019, 25(5): 521-538. DOI: 10.3748/wjg.v25.i5.521. |
| [3] |
BERUMEN J, BAGLIERI J, KISSELEVA T, et al. Liver fibrosis: Pathophysiology and clinical implications[J]. Wiley Interdiscip Rev Syst Biol Med, 2021, 13(1): e1499. DOI: 10.1002/wsbm.1499. |
| [4] |
ELLIS EL, MANN DA. Clinical evidence for the regression of liver fibrosis[J]. J Hepatol, 2012, 56(5): 1171-1180. DOI: 10.1016/j.jhep.2011.09.024. |
| [5] |
TAPPER EB, LOOMBA R. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(5): 274-282. DOI: 10.1038/nrgastro.2018.10. |
| [6] |
AGBIM U, ASRANI SK. Non-invasive assessment of liver fibrosis and prognosis: An update on serum and elastography markers[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(4): 361-374. DOI: 10.1080/17474124.2019.1579641. |
| [7] |
GUO T, HU B, YI WM, et al. Research advances in the serological diagnosis of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(11): 2579-2583. DOI: 10.3969/j.issn.1001-5256.2020.11.041. |
| [8] |
TEMEL Y İ, ASLAN ÇETIN B, KÖROĞLU N, et al. Inflammatory marker YKL-40 levels in intrahepatic cholestasis of pregnancy[J]. Gynecol Endocrinol, 2019, 35(7): 635-637. DOI: 10.1080/09513590.2018.1563889. |
| [9] |
ZHAO T, SU Z, LI Y, et al. Chitinase-3 like-protein-1 function and its role in diseases[J]. Signal Transduct Target Ther, 2020, 5(1): 201. DOI: 10.1038/s41392-020-00303-7. |
| [10] |
NGERNYUANG N, SHAO R, SUWANNARURK K, et al. Chitinase 3 like 1 (CHI3L1) promotes vasculogenic mimicry formation in cervical cancer[J]. Pathology, 2018, 50(3): 293-297. DOI: 10.1016/j.pathol.2017.09.015. |
| [11] |
ILMARINEN P, TUOMISTO LE, NIEMELÄ O, et al. YKL-40 and adult-onset asthma: Elevated levels in clusters with poorest outcome[J]. J Allergy Clin Immunol Pract, 2019, 7(7): 2466-2468.e3. DOI: 10.1016/j.jaip.2019.03.043. |
| [12] |
SUZUKI H, BOKI H, KAMIJO H, et al. YKL-40 promotes proliferation of cutaneous T-Cell lymphoma tumor cells through extracellular signal-regulated kinase pathways[J]. J Invest Dermatol, 2020, 140(4): 860-868.e3. DOI: 10.1016/j.jid.2019.09.007. |
| [13] |
SUN Y, SHI Z, LIU B, et al. YKL-40 mediates airway remodeling in asthma via activating FAK and MAPK signaling pathway[J]. Cell Cycle, 2020, 19(11): 1378-1390. DOI: 10.1080/15384101.2020.1750811. |
| [14] |
LIU L, ZHANG X, LIU Y, et al. Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations[J]. Respir Res, 2019, 20(1): 95. DOI: 10.1186/s12931-019-1051-9. |
| [15] |
JAFARI-NAKHJAVANI MR, GHORBANIHAGHJO A, BAGHERZADEH-NOBARI B, et al. Serum YKL-40 levels and disease characteristics in patients with rheumatoid arthritis[J]. Caspian J Intern Med, 2019, 10(1): 92-97. DOI: 10.22088/cjim.10.1.92. |
| [16] |
CHIRINOS JA, ORLENKO A, ZHAO L, et al. Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction[J]. J Am Coll Cardiol, 2020, 75(11): 1281-1295. DOI: 10.1016/j.jacc.2019.12.069. |
| [17] |
ŚCIBORSKI K, KULICZKOWSKI W, KAROLKO B, et al. Plasma YKL-40 levels correlate with the severity of coronary atherosclerosis assessed with the SYNTAX score[J]. Pol Arch Intern Med, 2018, 128(11): 644-648. DOI: 10.20452/pamw.4345. |
| [18] |
DEZSO Z, NIKOLSKY Y, SVIRIDOV E, et al. A comprehensive functional analysis of tissue specificity of human gene expression[J]. BMC Biol, 2008, 6: 49. DOI: 10.1186/1741-7007-6-49. |
| [19] |
ANDERSSON R, GEBHARD C, MIGUEL-ESCALADA I, et al. An atlas of active enhancers across human cell types and tissues[J]. Nature, 2014, 507(7493): 455-461. DOI: 10.1038/nature12787. |
| [20] |
SEITZ HK, BATALLER R, CORTEZ-PINTO H, et al. Alcoholic liver disease[J]. Nat Rev Dis Primers, 2018, 4(1): 16. DOI: 10.1038/s41572-018-0014-7. |
| [21] |
JOHANSEN JS, MØLLER S, PRICE PA, et al. Plasma YKL-40: A new potential marker of fibrosis in patients with alcoholic cirrhosis?[J]. Scand J Gastroenterol, 1997, 32(6): 582-590. DOI: 10.3109/00365529709025104. |
| [22] |
TRAN A, BENZAKEN S, SAINT-PAUL MC, et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease[J]. Eur J Gastroenterol Hepatol, 2000, 12(9): 989-993. DOI: 10.1097/00042737-200012090-00004. |
| [23] |
YOUNOSSI ZM, LOOMBA R, ANSTEE QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis[J]. Hepatology, 2018, 68(1): 349-360. DOI: 10.1002/hep.29721. |
| [24] |
KUMAGAI E, MANO Y, YOSHIO S, et al. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease[J]. Sci Rep, 2016, 6: 35282. DOI: 10.1038/srep35282. |
| [25] |
FU LK, SHENG LN, ZOU CY, et al. Correlation between serum fibrosis markers and intrahepatic fat content in patients with nonalcoholic fatty liver disease[J/CD]. Chin J Oper Proc Gen Surg(Electronic Version), 2019, 13(4): 385-387. DOI: 10.3877/cma.j.issn.1674-3946.2019.04.020. |
| [26] |
BUKH J. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control[J]. J Hepatol, 2016, 65(1 Suppl): s2-s21. DOI: 10.1016/j.jhep.2016.07.035. |
| [27] |
CHIGBU DI, LOONAWAT R, SEHGAL M, et al. Hepatitis C virus infection: Host virus interaction and mechanisms of viral persistence[J]. Cells, 2019, 8(4): 376. DOI: 10.3390/cells8040376. |
| [28] |
FONTANA RJ, DIENSTAG JL BONKOVSKY HL, et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C[J]. Gut, 2010, 59(10): 1401-1409. DOI: 10.1136/gut.2010.207423. |
| [29] |
ESMAT G, METWALLY M, ZALATA KR, et al. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C[J]. J Hepatol, 2007, 46(4): 620-627. DOI: 10.1016/j.jhep.2006.12.010. |
| [30] |
ZOHEIRY MM, HASAN SA, EL-AHWANY E, et al. Serum markers of epithelial mesenchymal transition as predictors of HCV-induced liver fibrosis, cirrhosis and hepatocellular carcinoma[J]. Electron Physician, 2015, 7(8): 1626-1637. DOI: 10.19082/1626. |
| [31] |
MEGAHED F, ZHOU X, SUN P. The interactions between HBV and the innate immunity of hepatocytes[J]. Viruses, 2020, 12(3): 385. DOI: 10.3390/v12030285. |
| [32] |
NIU XJ, LIU ZH, CUI FM, et al. Predictive value of systemic inflammatory indexes on progression of hepatitis B-related liver cirrhosis and hepatitis B virus-related hepatocellular carcinoma[J/CD]. Chin J Liver Dis(Electronic Edition), 2020, 12(2): 1-9. DOI: 10.3969/j.issn.1674-7380.2020.02.001. |
| [33] |
YANG Q, LYU XY, WANG Z. The value of YKL-40 and PCPE-1 in evaluating the degree of liver fibrosis in patients with chronic hepatitis B[J]. Chin Hepatol, 2019, 24(3): 309-312. DOI: 10.3969/j.issn.1008-1704.2019.03.033. |
| [34] |
YAN L, DENG Y, ZHOU J, et al. Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT[J]. Infection, 2018, 46(3): 385-393. DOI: 10.1007/s15010-018-1136-2. |
| [35] |
LONG X, HE X, OHSHIMO S, et al. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis[J]. Eur Respir J, 2017, 49(2). DOI: 10.1183/13993003.01924-2015. |
| [36] |
BIAN B, LI L, YANG J, et al. Prognostic value of YKL-40 in solid tumors: A meta-analysis of 41 cohort studies[J]. Cancer Cell Int, 2019, 19: 259. DOI: 10.1186/s12935-019-0983-y. |
| [37] |
FONTANA RJ, BONKOVSKY HL, NAISHADHAM D, et al. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis[J]. Clin Gastroenterol Hepatol, 2009, 7(2): 219-226. DOI: 10.1016/j.cgh.2008.10.034. |
| [38] |
NØJGAARD C, JOHANSEN JS, CHRISTENSEN E, et al. Serum levels of YKL-40 and PⅢNP as prognostic markers in patients with alcoholic liver disease[J]. J Hepatol, 2003, 39(2): 179-186. DOI: 10.1016/s0168-8278(03)00184-3. |
DownLoad: